ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,116.17
0.32%
US Tech 100
17,312.80
0.42%
다우존스 지수
38,386.09
0.38%
Bitcoin
63,399.66
-0.69%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) 뉴스

LXRX Lexicon Pharmaceuticals Inc

1.57
-0.01 (-0.63%)
30 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Lexicon Pharmaceuticals Inc LXRX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-0.01 -0.63% 1.57 08:55:31
개장가 저가 고가 종가 전일 종가
1.61 1.55 1.70 1.56 1.58
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
29/04/202422:00GLOBELonnel Coats Retires as Chief Executive Officer and Board..
29/04/202420:00GLOBELexicon Pharmaceuticals to Host First Quarter 2024 Financial..
18/04/202421:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03/04/202421:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
25/03/202422:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12/03/202421:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
12/03/202405:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11/03/202420:26EDGAR2Form 8-K - Current report
11/03/202420:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11/03/202420:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11/03/202420:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
01/03/202406:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/03/202406:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202406:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/01/202421:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
30/12/202307:29EDGAR2Form 8-K - Current report
30/12/202307:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/12/202306:04EDGAR2Form 8-K - Current report
22/12/202306:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30/11/202321:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22/11/202321:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
18/11/202306:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202307:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202304:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
11/11/202306:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
09/11/202306:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202321:22EDGAR2Form 8-K - Current report
08/11/202321:00GLOBELexicon Pharmaceuticals Reports Third Quarter 2023 Financial..
03/11/202322:00GLOBELexicon Pharmaceuticals to Host Third Quarter 2023 Financial..
02/11/202322:00GLOBEData on Early Clinical Benefit for INPEFA® (Sotagliflozin)..
01/11/202322:00GLOBEINPEFA® (Sotagliflozin) Receives Coverage From Express..
01/11/202305:01GLOBELexicon Strengthens Management Team With Two New Executives
31/10/202305:01GLOBENew Data Relating to Sotagliflozin to be Presented at the..
18/10/202305:01GLOBEData From Two Studies Demonstrating Positive Financial..
12/10/202305:06EDGAR2Form 8-K - Current report
12/10/202305:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202305:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/10/202322:00GLOBEData Demonstrating Financial Impact of INPEFA®..
10/10/202305:01GLOBEINPEFA® (Sotagliflozin) Receives Preferred Formulary Status..
09/10/202321:00GLOBETom Garner Joins Lexicon as Senior Vice President and Chief..
28/09/202322:00GLOBELexicon to Present Post Hoc Analysis of Scored Clinical..
26/09/202322:00GLOBELexicon to Present Study Results Relating to Sotagliflozin..

최근 히스토리

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유